Egészségtudományi Intézet

Permanent URI for this community

https://krepozit.kre.hu/handle/123456789/372

Browse

Browsing Egészségtudományi Intézet by Author "Dr. Bányász Edina"

Now showing 1 - 1 of 1
  • Thumbnail Image
    Item
    Open Access
    Kezdeti tapasztalataink spinalis muscularis atrophiában szenvedő gyermekek intravénás génterápiájával
    (2020) Dr. Mikos Borbála; Dr. Gergely Anita; Dr. Balázsfi Réka; Dr. Bányász Edina; Dr. Gyömörei Beáta; Dr. Hantos Mónika; Dr. Czelecz Judit; Dr. Jakus Rita; Dr. Kárász Hajnalka; Dr. Zilahy Mónika; Dr. Molnár Eszter; Dr. Paraicz Éva; Dr. Csohány Ágnes; Dr. Szénási Fanni; Dr. Vendégh Lejla; Dr. Fogarasi András; Dr. Velkey György János
    Congenital spinal muscular atrophy is a rare, progressive neurodegenerative disease, one of the major genetic causes of childhood death. The possibilities of medicine to curb its progression and to delay and mat the disease's complications were limited before the 21st century. Therefore, children with the most severe genetic defects were usually lost before their second birthday. Advances in genetic diagnostics allow for early diagnosis, prediction of severity and expected progression. Using intrathecal nusinersen (available in Hungary since 2018), clinical results based on a large number of patients are convincing. Experience with the new intravenous gene therapy (onasemnogene abeparvovec) available from 2019 is still based on a less number of patients. It was used in Hungary in Bethesda Hospital in five children based on strict professional criteria and preparations. Our paper summarizes the most important efficacy and safety data of the first three consecutive patients. According to our experiences, the product helps to improve movement performance. Side effects are mainly reversible elevations of liver enzymes and serum troponin-I levels, thrombocytopenia and granulocytopenia. Therefore, we found that it is important to monitor patients closely on a long-term basis in order to detect and eliminate side effects early.